Renal Transplantation Is Associated with Improved Clinical Outcomes in Nephrogenic Systemic Fibrosis

Table 2

Improvement rate between treatment modalities.

Groups	Without adjustments			After adjustment for age and time to treat
	HR	CI 95%	𝑃	HR	CI 95%	𝑃
T2 versus T1	7.69	3.69–15.97	<0.0001	9.69	3.52–26.62	<0.0001
T3 versus T1	25.24	9.16–69.54	<0.0001	27.75	8.12–94.88	<0.0001
T4 versus T1	6.59	2.69–16.14	<0.0001	8.41	2.38–29.71	<0.001
T3 versus T2	3.28	1.43–7.52	0.004	2.87	1.15–7.11	0.023
T4 versus T2	0.86	0.43–1.69	0.657	0.87	0.35–2.18	0.763

T1: patients who received no treatment other than dialysis. T2: patients who received NSF specific treatment other than renal transplantation. T3: patients who received only renal transplantation. T4: patients who received NSF specific treatment followed by renal transplantation. HR: Hazard ratio. CI 95%: confidence interval 95%. 𝑃: probability value.